Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.91% | 1.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.91% | 1.38% | |||
| Cost of Revenue | 235.82% | -954.73% | |||
| Gross Profit | -50.98% | 38.27% | |||
| SG&A Expenses | 12.30% | -17.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28,500.10% | -100.72% | |||
| Operating Income | -78.95% | 76.29% | |||
| Income Before Tax | -82.60% | 31.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -82.60% | 31.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 63.36% | -22.48% | |||
| Net Income | -93.93% | 37.57% | |||
| EBIT | -78.95% | 76.29% | |||
| EBITDA | -78.79% | 76.03% | |||
| EPS Basic | -94.04% | 75.11% | |||
| Normalized Basic EPS | -118.66% | 818.12% | |||
| EPS Diluted | -94.06% | 74.88% | |||
| Normalized Diluted EPS | -119.01% | 620.36% | |||
| Average Basic Shares Outstanding | 1.89% | -21.44% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.15% | |||
| Dividend Per Share | 0.00% | 6.82% | |||
| Payout Ratio | 15.55% | -0.19% | |||